Effects of Forest Therapy on Physical and Psychological Parameters in the General Population - a Randomized Controlled Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany, 14109
- Recruiting
- Charité Hochschulambulanz für Naturheilkunde am Immanuel Krankenhaus
-
Contact:
- Miriam Rösner, Study nurse
- Phone Number: 00493080505682
- Email: m.roesner@immanuel.de
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Ability to Consent
Exclusion Criteria:
- Serious acute or chronic illness
- Immobility or limitation of mobility due to orthopedic, neurologic, or other medical causes
- Participation in another study
- Serious mental illness
- Pregnancy and lactation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
No Intervention: Waiting list
|
|
|
Experimental: Active forest therapy
|
Participants take part in a two-hour active clinical forest therapy in Berlin-Wannsee on two days (with a break day in between).
In this setting, a trained clinical forest therapist teaches exercises on the perception of nature and the connection between nature and health.
|
|
Active Comparator: Passive forest therapy
|
Participants take part in a two-hour passive clinical forest therapy in Berlin-Wannsee over two days (with a break day in between).
In this setting, a trained clinical forest therapist will guide participants to various locations in the forest where participants can stay and let nature have its effect on them.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Profile of Mood States (POMS)
Time Frame: Change from baseline POMS score at 3 months
|
Change from baseline POMS score at 3 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Profile of Mood States (POMS)
Time Frame: Baseline, day 1, day 3, 1 week, 3 months
|
Baseline, day 1, day 3, 1 week, 3 months
|
|
|
Perceived Benefits of Nature Questionnaire (PBNQ)
Time Frame: Baseline, 1 week, 3 months
|
Baseline, 1 week, 3 months
|
|
|
Subjective Vitality Scale state (SVS-G state)
Time Frame: Baseline, day 1, day 3, 1 week, 3 months
|
Baseline, day 1, day 3, 1 week, 3 months
|
|
|
Complaint List (B-LR)
Time Frame: Baseline, 1 week, 3 months
|
Baseline, 1 week, 3 months
|
|
|
Perceive Stress Questionaire (PSQ)
Time Frame: Baseline, day 1, day 3, 1 week, 3 months
|
Baseline, day 1, day 3, 1 week, 3 months
|
|
|
Freiburger Fragebogen zur Achtsamkeit (FFA)
Time Frame: Baseline, 1 week, 3 months
|
Baseline, 1 week, 3 months
|
|
|
Hospital Anxiety and Depression Scale (HADS)
Time Frame: Baseline, 1 week, 3 months
|
The scale ranges from 0 to 3. Higher scores correspond to higher levels of anxiety and/or depression.
|
Baseline, 1 week, 3 months
|
|
Perceived Stress Scale (PSS)
Time Frame: Baseline, 1 week, 3 months
|
The scale ranges from 0 to 4. Higher scores correspond to higher levels of perceived stress.
|
Baseline, 1 week, 3 months
|
|
Allgemeine Selbstwirksamkeit Kurzskala (ASKU)
Time Frame: Baseline, 1 week, 3 months
|
The scale ranges from 1 to 5. Higher scores correspond to better outcomes.
|
Baseline, 1 week, 3 months
|
|
State-Trait Anxiety Inventory (STAI)
Time Frame: Baseline, day 1, day 3, 1 week, 3 months
|
The scale ranges from 1 to 8. Higher scores correspond to higher levels of anxiety (after recoding three inverted items).
|
Baseline, day 1, day 3, 1 week, 3 months
|
|
PROMIS Scale v1.2 - Global Health
Time Frame: Baseline, 1 week, 3 months
|
The scale ranges from 1 to 5, where 1 is the lowest level and 5 is the highest level.
Higher scores reflect better functioning.
|
Baseline, 1 week, 3 months
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Heart Rate Variability (HRV)
Time Frame: Baseline, 1 week
|
24h measuring by Faros 180
|
Baseline, 1 week
|
|
Qualitative interviews
Time Frame: 1 week and 8 weeks after inclusion
|
Qualitative assessment will be carried out in qualitative interviews in 20 patients participating in the study.
The interviews will be recorded, transcribed and analyzed with qualitative content analysis.
|
1 week and 8 weeks after inclusion
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- KWT2
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.